Continuous pharmaceutical manufacturing offers potential flexibility, quality, and economic advantages over batch processing, both in process development and manufacturing for the pharmaceutical sector. Over the past decade, there have been significant advancements in science and engineering to support the implementation of continuous pharmaceutical manufacturing. These investments, along with the adoption of the QbD paradigm for pharmaceutical development and the advancement of PAT for designing, analyzing, and controlling manufacturing, have progressed the scientific and regulatory readiness for continuous manufacturing. Building on this progress, research efforts should continue in several key areas to address the remaining implementation challenges.
